Brown & Brown (BRO) Earnings Dates, Call Summary & Reports

672 Followers

Earnings Data

Report Date

Jul 27, 2026

After Close (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

1.09

Last Year’s EPS

1.03

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 16 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Apr 27, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call highlighted strong consolidated growth driven by the Accession acquisition, meaningful contingent commission upside, margin expansion, improved cash generation and clear AI/technology initiatives expected to drive long-term productivity and revenue. Offsetting these positives are near-term organic growth headwinds ex-contingents (driven by CAT property rate declines and a pharmacy revenue-model transition), comparable impacts from prior-year flood claims, litigation-related client losses (~$31M annualized) and integration-related margin and cash conversion drag. Management expects sequential organic improvement and full-year benefits from Accession synergies and AI investments.

Company Guidance

Management guided to modest, sequential organic growth improvement each quarter (Q2 expected to be relatively flat on an organic ex-contingents basis due to heavy CAT property placements, with the back half of the year running higher and an informal upper bound for later-year organic around ~2.5%), and said contingent commissions should be up for the year (Q1 contingents rose roughly $54M and last year’s total was about $255M). They reiterated Accession is being integrated (Q1 revenues recognized ≈ $445M, Q1 drag on consolidated adjusted EBITDAC ≈ 200 bps, full‑year Accession adjusted EBITDAC expected ≈ 35%, and $30M–$40M of EBITDA synergies targeted this year). Financial cadence assumptions include continued strong cash generation (Q1 cash flow from operations > $260M, up ≈ $50M or 23%, CFO/total revenue ≈ 14% vs 15% LY) while balancing capital between delevering, M&A, dividends and buybacks (recent $350M repurchase reduced shares by ~5M; weighted average shares ≈ 337M; dividends per share up 10%). Key quarter metrics cited that underpin the outlook: consolidated revenue $1.9B (+35.4%), adjusted EBITDAC up 36.6% with a 38.5% margin (+40 bps), adjusted EPS $1.39 (+7.8%), Retail organic incl. contingents 1.3% (excl. 1%; a 50–100 bps headwind expected from a pharmacy revenue model change), Specialty Distribution organic incl. contingents +3.9% (excl. -2%; ~300 bps drag from ~$12M prior‑year flood claims), and an effective tax rate of 22.8%.

Strong Consolidated Revenue Growth

Total revenues of $1.9 billion, up 35.4% year-over-year, driven primarily by the Accession acquisition (≈$445 million of recognized revenues for the quarter).

Contingent Commissions Upside

Contingent commissions increased by approximately $54 million consolidated (≈$52 million in Specialty Distribution), including $22 million attributable to Accession and ~$30 million from favorable underwriting performance; company expects contingents to be up for the full year.

Margin and Profitability Expansion

Adjusted EBITDAC grew 36.6% with an EBITDAC margin increase of 40 basis points to 38.5%; Specialty Distribution EBITDAC margin rose 30 bps to 40.8%.

Earnings and Cash Generation

Adjusted diluted net income per share increased ~7.8% to $1.39; generated over $260 million of cash flow from operations (up ~$50 million or 23% year-over-year).

Retail and Specialty Organic Performance (with Contingents)

Retail organic growth including contingents of 1.3% (excluding contingents 1.0%); Specialty Distribution organic revenue including contingents +3.9% (excluding contingents -2.0%), showing underlying strength when contingent commissions are included.

Capital Allocation Actions

Returned capital via $350 million of share repurchases (reduced share count by ~5 million) and a 10% increase in dividends per share; continue balanced deployment across repurchases, M&A, dividends and delevering.

Accession Integration and Synergies

Accession integration on track with targeted EBITDA synergies of $30–$40 million expected this year; management expects Accession margins to approximate ~35% for the full year.

Technology & AI-driven Productivity Initiatives

Investments in data/AI: AI agents automating >25% of certain submission processes, policy-checking agents, and a billing automation platform saving >50,000 hours annually — positioned to drive revenue growth and operating leverage over time.

Brown & Brown (BRO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BRO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 27, 2026	2026 (Q2)	1.09 / -	1.03	―	―	―
Apr 27, 2026	2026 (Q1)	1.36 / 1.39	1.29	7.75% (+0.10)
Jan 26, 2026	2025 (Q4)	0.90 / 0.93	0.86	8.14% (+0.07)
Oct 27, 2025	2025 (Q3)	0.94 / 1.05	0.91	15.38% (+0.14)
Jul 28, 2025	2025 (Q2)	0.99 / 1.03	0.93	10.75% (+0.10)
Apr 28, 2025	2025 (Q1)	1.29 / 1.29	1.14	13.16% (+0.15)
Jan 27, 2025	2024 (Q4)	0.77 / 0.86	0.58	48.28% (+0.28)
Oct 28, 2024	2024 (Q3)	0.88 / 0.91	0.71	28.17% (+0.20)
Jul 22, 2024	2024 (Q2)	0.88 / 0.93	0.68	36.76% (+0.25)
Apr 22, 2024	2024 (Q1)	1.07 / 1.14	0.84	35.71% (+0.30)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BRO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 27, 2026	$65.93	$62.95	-4.51%
Jan 26, 2026	$79.20	$73.73	-6.91%
Oct 27, 2025	$87.12	$81.78	-6.13%
Jul 28, 2025	$101.67	$91.09	-10.40%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.